Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents

Clinical Oncology

Volumn 25, Issue 7, 2013, Pages 435-444

  Poon, M ^a   Zeng, L ^a   Zhang, L ^a   Lam, H ^a   Emmenegger, U ^a   Wong, E ^a   Bedard, G ^a   Lao, N ^a   Chow, R ^a   Chow, E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Orthopaedic surgery; Palliative radiation; Pathological fracture; Skeletal related events

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MODIFYING AGENT; DENOSUMAB; DRUG; PAMIDRONIC ACID; PLACEBO; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BLADDER CANCER; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETAL RELATED EVENT; SOLID TUMOR;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878657019     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.03.003     Document Type: Article

References (27)

1. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88(5):1082-1090.
2. Costa L., Major P.P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009, 6(3):163-174.
3. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. JClin Oncol 1999, 17(3):846-854.
4. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. JClin Oncol 2011, 29(9):1125-1132.
5. Saad F., Chen Y.M., Gleason D.M., Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007, 5(6):390-396.
6. Sherry M.M., Greco F.A., Johnson D.H., Hainsworth J.D. Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 1986, 58(1):178-182.
7. Plunkett T.A., Smith P., Rubens R.D. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000, 36(4):476-482.
8. Saad F., Gleason D.M., Murray R., et al. Arandomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. JNatl Cancer Inst 2002, 94(19):1458-1468.
9. Zeng L., Chow E., Zhang L., et al. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Support Care Cancer 2012 Dec, 20(12):3307-3313.
10. Polascik T.J. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 2009, 3:27-40.
11. Delea T., Langer C., McKiernan J., et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67(5-6):390-396.
12. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. JClin Oncol 2010, 28(35):5132-5139.
13. Dearnaley D.P., Sydes M.R., Mason M.D., et al. Adouble-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). JNatl Cancer Inst 2003, 95(17):1300-1311.
14. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. NEngl J Med 1996, 335(24):1785-1791.
15. Small E.J., Smith M.R., Seaman J.J., Petrone S., Kowalski M.O. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. JClin Oncol 2003, 21(23):4277-4284.
16. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: arandomized, placebo-controlled trial. JClin Oncol 2005, 23(15):3314-3321.
17. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98(5):962-969.
18. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100(12):2613-2621.
19. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822.
20. Ristevski B., Jenkinson R.J., Stephen D.J., et al. Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg 2009, 52(4):302-308.
21. Harrington K.D. Orthopedic surgical management of skeletal complications of malignancy. Cancer 1997, 80(8 Suppl.):1614-1627.
22. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer 2008, 112(5):1001-1010.
23. Shiue K., Sahgal A., Chow E., et al. Management of metastatic spinal cord compression. Expert Rev Anticancer Ther 2010, 10(5):697-708.
24. Khan L., Kwong J., Nguyen J., et al. Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic. Support Care Cancer 2012, 20(3):549-555.
25. Higginson I.J., Finlay I., Goodwin D.M., et al. Do hospital-based palliative teams improve care for patients or families at the end of life?. JPain Symptom Manage 2002, 23(2):96-106.
26. Lagman R., Walsh D. Integration of palliative medicine into comprehensive cancer care. Semin Oncol 2005, 32(2):134-138.
27. Carteni G., Bordonaro R., Giotta F., et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006, 11(7):841-848.